The firm reported that revenues for Nanosphere, which Luminex acquired in 2016, were up 39 percent year-over-year.
The bank rated companies like Thermo Fisher Scientific and Agilent at Buy, Illumina and PerkinElmer at Hold, and Myriad Genetics and Luminex at Sell.
Executives from Luminex and Exact Sciences provided updates on their companies at the 35th Annual JP Morgan Healthcare Conference in San Francisco.
The firm also reported that 2016 preliminary revenues were up 14 percent, and that Nanosphere MDx platform revenues rose 32 percent.
The assay is designed to detect Group B Streptococcus colonization in pregnant women using vaginal-rectal swab specimens.
Mergers and acquisitions in the omics space rose for the second year in a row, but the increase was significantly less than the 33 percent uptick in 2015 deals.
The company attributed the increase to gains in its molecular business, including $7.4 million in revenues from Nanosphere, which Luminex acquired in June.
Industry executives said they believe ASRs are key components for laboratory directors who need to quickly develop critical diagnostic tests.
The test was designed by diagnostics maker GenArraytion and uses the Luminex xMAP technology.
The PCR-based assays run on the company's Aries system, which itself received FDA clearance in October 2015.
A Minnesota toddler given a gene therapy to treat her spinal muscular atrophy is now walking, according to Newsweek.
NBC Bay Area reports a California lab has been certified to conduct forensic mitochondrial DNA sequencing.
The New York Times reports on how environmental DNA sampling could monitor endangered species.
In Cell this week: proteomic, genomic, and transcriptomic analysis of endometrial cancer; deep neural network learning-based approach to antibiotic discovery; and more.